Greater Transplant-free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls.
Sign Up to like & getrecommendations! Published in 2022 at "Gastroenterology"
DOI: 10.1053/j.gastro.2022.08.054
Abstract: BACKGROUND AND AIMS The POISE randomized double-blind placebo-controlled trial demonstrated that obeticholic acid (OCA) reduced biomarkers associated with adverse clinical outcomes (ALP, bilirubin, AST, ALT) in patients with primary biliary cholangitis (PBC). The objective of… read more here.
Keywords: primary biliary; trial; biliary cholangitis; obeticholic acid ... See more keywords